- Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This study is looking at a new medicine called sonelokimab for adults with moderate to severe hidradenitis suppurativa (HS). Researchers want to see if it's safe and effective compared to a placebo (a dummy medicine) in improving HS symptoms.
For: Hidradenitis SuppurativaUnited States · Bulgaria · Canada - RecruitingPHASE3
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
This study is testing a new medicine called sonelokimab for adults with psoriatic arthritis that hasn't responded well to previous treatments. We want to see if it's safe and helps improve their symptoms compared to a dummy treatment or an existing medicine.
For: Arthritis, PsoriaticUnited States · Bulgaria · Canada - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (M1095-HS-302)
This study is testing a new medicine, sonelokimab, for adults with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it's safe and helps improve HS over 16 weeks.
For: hidradenitis suppurativa (HS)Netherlands · Slovakia · Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (M1095-HS-301)
This study is testing a new medicine, sonelokimab, for adults with moderate to severe hidradenitis suppurativa (HS). It compares sonelokimab to a dummy treatment (placebo) to see if it improves HS symptoms and is safe to use.
For: hidradenitis suppurativa (HS)Norway · Italy · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, multicentre open-label study to explore the effects of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris
This study is looking at a new medicine called sonelokimab for people with a skin condition called palmoplantar pustulosis (PPP). It wants to see how well the medicine works to reduce the redness and spots on hands and feet after 16 weeks.
For: Palmoplantar PustulosisGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 open-label imaging study to explore the effects of sonelokimab in patients with active axial spondyloarthritis
This study is looking at a new medicine called sonelokimab for people with a type of arthritis affecting the spine, called axial spondyloarthritis. It aims to see how the medicine might reduce inflammation in the back and hips over 12 weeks, using special scans.
For: axial spondyloarthritisGermany - Enrolling by invitationPHASE3
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
This study looks at how safe and effective a new medicine, Sonelokimab, is for a long time in people with moderate to severe Hidradenitis Suppurativa. It's for those who have already been in similar Sonelokimab studies.
For: Hidradenitis SuppurativaUnited States · Belgium · Bulgaria - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
This study looks at a new medicine called sonelokimab for psoriatic arthritis. It checks how safe and helpful the medicine is over a long time for people who have already tried it in another study. Doctors will monitor side effects and overall health.
For: psoriatic arthritis (PsA)Estonia · Croatia · Slovakia